The healthcare industry has been slow to adopt new technologies, including the cloud. However, industry-wide demand to use health data to improve system efficiency, deliver value-based care and enable productive collaborations is driving investment in cloud solutions. [Read more…]

Change Healthcare and Zebra Medical Vision today announced an agreement to create solutions that deliver artificial intelligence solutions to complex radiology reporting environments. Change Healthcare’s proven radiology solutions, along with Zebra Medical Vision’s algorithms, will benefit radiologists and other imaging specialists by improving the efficiency of routine tasks and the effectiveness of workflow in the radiologist reading environment. [Read more…]

Deloitte, a leader in life sciences and health care consulting services, announced today that it has achieved Amazon Web Services (AWS) Life Sciences Competency status. This designation recognizes Deloitte for its ability to build successful life sciences solutions on AWS to help customers conduct drug discovery, manage clinical trials, engage in manufacturing and distribution activities, and conduct research and development of novel genetic-based treatments and companion diagnostics. [Read more…]

Majorly, chronic myelogenous leukemia (CML) occurs in adults, however, it sometimes occurs in children as well. However, targeted drugs called Tyrosine-Kinase Inhibitors (TKIs) have been effective in providing long-term survival rates. Meanwhile, the Food and Drug Administration (FDA) has recently approved dasatinib (Sprycel) for the treatment of chronic myelogenous leukemia in children. As the chronic myeloid leukemia is more aggressive in younger patients, the approval of drugs can help in effective treatment. [Read more…]

MyDx, Inc. (OTC: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it filed patents on its revolutionary, second smart device — The ECOSmartPenTM — and is now accepting Pre-Orders. [Read more…]

WellCare of Nebraska, a subsidiary of WellCare Health Plans, Inc. (NYSE: WCG), announced today that its medical director, Dr. Stephen Lazoritz, has received a governor appointment to the newly established Palliative Care and Quality of Life Advisory Council. [Read more…]

Research and knowledge on the effects of nut consumption on human health has increased in recent years, suggesting that nut consumption may play a key role in the prevention of chronic diseases, such as diabetes and cardiovascular disease (CVD), among others. [Read more…]

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Children’s Hospital & Medical Center of Omaha, one of U.S. News and World Report’s Best Children’s Hospitals for Cardiology and Heart Surgery, have signed a 10-year, strategic partnership to help drive innovation in pediatric care. Working together, Philips and Children’s will look to identify opportunities to enhance the quality and cost effectiveness of patient services, including focusing on connected solutions in diagnostic imaging, patient monitoring, respiratory solutions and clinical informatics. [Read more…]

Regentis Biomaterials announced today the start of its Phase III pivotal clinical trial of GelrinC for the treatment of focal knee cartilage defects with successful surgery on three patients in the U.S. and Denmark. These procedures are part of a Food and Drug Adminstration (FDA) approved Investigational Device Exemption (IDE) clinical study to compare GelrinC to microfracture, the current standard of care treatment. The clinical study will be used to support a Pre-market Approval Application (PMA) which will allow Regentis to market GelrinC in the U.S. [Read more…]

Upsher-Smith Laboratories, LLC. (Upsher-Smith) today announced the launch of KLOR-CON® Powder (Potassium Chloride) for oral solution, 20 mEq. The Company received approval of an abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for this product, which will be marketed and distributed by Upsher-Smith. Sandoz, Inc. will continue as the licensed marketer and distributor in the U.S. for the balance of the KLOR-CON® line of potassium products. [Read more…]